Stay updated on Tisotumab Vedotin Efficacy in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tisotumab Vedotin Efficacy in Solid Tumors Clinical Trial page.

Latest updates to the Tisotumab Vedotin Efficacy in Solid Tumors Clinical Trial page
- ChecktodayChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedFooter shows a minor version update from Revision: v3.4.1 to v3.4.2. No study content or essential page functionality appears affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No substantive changes to study information or site functionality are evident.SummaryDifference0.0%

- Check44 days agoChange DetectedThe 'Last Update Posted (Estimated)' label was replaced with a new 'Last Update Posted' label, removing the estimated qualifier. This is a minor UI change that does not affect the study data or its interpretation, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedThe study now indicates transition to a long-term extension phase (LTEP) with Part E closed to enrollment; Part D and Part F closed, and Part G enrolling only for HNSCC with its cohort not opened. Part A dosing is now listed as every 3 weeks, and Part D dosing on Day 1 of each 21-day cycle; the page reports 172 locations.SummaryDifference0.5%

- Check73 days agoChange DetectedAdded a comprehensive list of trial locations across multiple states and countries, and removed several locations from the list.SummaryDifference2%

Stay in the know with updates to Tisotumab Vedotin Efficacy in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tisotumab Vedotin Efficacy in Solid Tumors Clinical Trial page.